ICDM 2026

Research group sessions

Heterogeneity in DKD Bridging the gap between renal pathology and clinical outcomes in DKD Chair(s): Hunjoo Ha, Nan Hee Kim Thursday 15 October, 14:30-15:30 Room 4

Diabetic kidney disease (DKD) follows heterogeneous clinicopathological trajectories, complicating prognosis and treatment. This session explores how renal pathologic patterns relate to disease progression and how clinical pharmacological approaches can help decode this heterogeneity, linking kidney injury to long-term outcomes. It highlights pathology-centered biomarkers that translate structural lesions into measurable, non-invasive signals. By integrating pathologic insights with clinical pharmacology, the session aims to advance precision risk prediction and individualized therapy.

RS1-L1 Ju-Young MoonKyung Hee University, Korea: Heterogeneity of clinicopathological trajectories in diabetic kidney disease

RS1-L2 Hiddo Lambers HeerspinkUniversity Medical Center Groningen, Netherlands: Decoding DKD heterogeneity: clinical pharmacological approaches to bridge renal injury and long-term outcomes

Multi-omics at the frontiers of metabolism and aging Decoding metabolism and aging through multi-omics—from systemic signals to tissue architecture and cellular mechanisms Chair(s): SungHee Choi, Hail Kim Thursday 15 October, 14:30-15:30 Room 5

This session will showcase how state-of-the-art multi-omics technologies are redefining our understanding of metabolism, tissue biology, and aging. Through integrative analyses spanning circulating factors, spatial tissue architecture, and mitochondrial proteostasis, the session will provide new insights into systemic adaptation, cellular heterogeneity, and metabolic dysfunction in health and disease. The session will be particularly valuable for researchers and clinicians in metabolism, aging, and precision medicine, offering novel conceptual frameworks and translational opportunities for biomarker discovery and therapeutic development.

RS2-L1 Hyon-Seung YiChungnam National University, Korea: Plasma and extracellular vesicle multi-omics responses to a single bout of resistance and endurance exercise in humans

RS2-L2 Chang-Myung OhGIST, Korea: Aging reshapes sex- and diet-specific metabolic plasticity across the adipose–liver–muscle axis

RS2-L3 Cheng ZhangKing’s College London, UK: Spatially resolved metabolic flux modeling of liver tissue: integrating transcriptomics, metabolomics, and metallomics via genome-scale constraint-based modeling

Shared pathophysiology of aging and diabetes The complex nexus of aging and diabetes: metabolic, muscular, and renal perspectives Chair(s): Dong Hyeok Cho, Tae Seo Sohn Thursday 15 October, 14:30-15:30 Room 6

This session explores the intricate pathophysiological interplay between aging and diabetes in older adults. Specifically, it elucidates the mechanistic overlap between metabolic aging and insulin resistance, demonstrating how physiological aging exacerbates glycemic dysregulation. It further examines the muscle-diabetes interface, specifically focusing on sarcopenia and malnutrition. Additionally, the unique clinical and pathophysiological complexities of chronic kidney disease in this demographic are comprehensively addressed. Ultimately, understanding these shared pathways will pave the way for advancing personalized, targeted therapies in geriatric care.

RS3-L1 Jong Han ChoiKonkuk University, Korea: Metabolic aging and insulin resistance: mechanistic overlap in older adults

RS3-L2 Hye Soo ChungHallym University, Korea: Sarcopenia and type 2 diabetes in older adults: pathophysiological mechanisms and therapeutic strategies

RS3-L3 Eun RohSeoul National University, Korea: Chronic kidney disease in older adults with diabetes: clinical and pathophysiological perspectives

Panel discussion

RS3-P1
SungWan ChunPohang Semyung Christianity Hospital, Korea
RS3-P2
Sung Hoon YuHanyang University, Korea
RS3-P3
Jaehyun BaeHallym University, Korea

CGM, AID, insulin What’s new in CGM and AID for insulin-treated patients? Chair(s): Jae Hyeon Kim, Jae Hyoung Cho Thursday 15 October, 15:40-16:40 Room 2

This session covers the latest advances in diabetes technology. Experts will detail the interpretation of core CGM metrics and AGP reports, including the GMI/A1C discordance research recently published in Diabetes Care. We will examine cutting-edge RCT results for the world's first Stage 5 connected insulin pen, and hear from a Medtronic expert on the imminent commercialization of fully automated insulin delivery (AID). This session is essential for advancing clinical practice with the latest technology.

RS4-L1 Sang-Man JinSungkyunkwan University, Korea: Updates in CGM interpretation: from core metrics and AGP to GMI–A1C discordance

RS4-L2 Ji Yoon KimKyung Hee University, Korea: Results from the first clinical trial of a stage 5 connected insulin pen

RS4-L3 John ShinMiniMed, USA: Pathways to fully automated insulin delivery: scientific feasibility and remaining barriers

Holistic MASLD assessment Comprehensive diagnostic tools for MASLD: evaluating steatosis and fibrosis Chair(s): Eun-Jung Rhee, Kenneth Cusi Thursday 15 October, 15:40-16:40 Room 3

Focusing on comprehensive MASLD diagnostics, this session systematically reviews noninvasive tools for evaluating steatosis and fibrosis. Lectures address current clinical utilities of advanced imaging, blood-based biomarkers, and emerging innovations like AI and radiomics. Ultimately, this session highlights a pivotal paradigm shift toward precision medicine, offering a transformative framework for future clinical screening and risk-stratification strategies.

RS5-L1 Chan Wah KheongUniversiti Malaya, Malaysia: Noninvasive imaging for MASLD: from transient elastography to magnetic resonance imaging

RS5-L2 Hye Won LeeYonsei University, Korea: Blood-based biomarkers and scores: practical approaches to fibrosis assessment

RS5-L3 Terry Cheuk-Fung YipThe Chinese University of Hong Kong, Hong Kong, China: Future directions in MASLD diagnostics: AI, radiomics, and multi-omics approaches

β-cell dysfunction Compensatory and genetic determinants of β-cell function in diabetes Chair(s): Ki-Ho Song, Kyuchang Won Thursday 15 October, 15:40-16:40 Room 4

Progressive β-cell dysfunction is a key feature of diabetes development and progression. This session will cover recent advances in β-cell biology, including mechanisms of compensation, dysfunction, and genetic susceptibility. Prof. Hyunki Kim will present single-cell insights into β-cell adaptation under metabolic stress, Prof. Jinsook Son will discuss ALDH1A3 as a therapeutic target for β-cell preservation, and Prof. Joon Ho Moon will explore the role of a diabetes-associated PAX4 variant in β-cell function. Together, these presentations will provide new perspectives on preserving and restoring functional β-cell mass in diabetes.

RS6-L1 Hyunki KimKAIST, Korea: Compensatory signatures of β-cells and islet stellate cells in human obesity

RS6-L2 Jinsook SonCornell University, USA: An unbiased drug screen to identify agents that reverse β-cell dedifferentiation

RS6-L3 Joon Ho MoonSeoul National University, Korea: Impact of type 2 diabetes-associated PAX4 variant on pancreatic beta cell function

Diabetic neuropathy, cardiac autonomic neuropathy, management Addressing the systemic burden of diabetic neuropathy: vascular and mitochondrial dysfunction, advanced diagnostics, and comprehensive management Chair(s): Ie Byung Park, Rayaz A. Malik Thursday 15 October, 15:40-16:40 Room 5

This session explores diabetic neuropathy through the lens of vascular injury, mitochondrial dysfunction, advanced autonomic diagnostics, and multimodal pain management. Integrating mechanistic insights with practical clinical strategies, the discussion will highlight how early detection and comprehensive care may reshape outcomes in diabetic neuropathy and cardiac autonomic neuropathy. The session underscores a future-oriented approach to precision evaluation and treatment.

RS7-L1 Soo Kyoung KimGyeongsang National University, Korea: Microvascular angiopathy and mitochondrial dysfunction: the pivotal drivers of diabetic nerve damage and therapeutic targets

RS7-L2 Ho Chan ChoKeimyung University, Korea: The search for biomarkers for early prediction of diabetic peripheral neuropathy

RS7-L3 Ji HuThe Second Affiliated Hospital of Soochow University, China: Epigenetic regulation of diabetic neuropathy

Panel discussion

RS7-P1
Ji Min KimChungnam National University, Korea
RS7-P2
Kyung Ae LeeJeonbuk National University, Korea
RS7-P3
Chong Hwa KimSejong General Hospital, Korea

Clinical updates in gestational diabetes mellitus Clinical updates in gestational diabetes mellitus Chair(s): Hak Chul Jang, Soo Heon Kwak Thursday 15 October, 15:40-16:40 Room 6

This session will present contemporary evidence on gestational diabetes mellitus, covering early GDM, maternal glycemic management including continuous glucose monitoring, pregnancy outcomes, and the long-term health of offspring. By integrating global evidence with Korean clinical data, the session will provide practical insights into optimizing care of GDM and discuss future directions for improving maternal and offspring health.

RS8-L1 Ronald MaThe Chinese University of Hong Kong, China: Long-term complications of gestational diabetes: challenges and opportunities

RS8-L2 Viswanathan MohanMadras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, India: Early GDM consensus statement

RS8-L3 Hun Jee ChoeHallym University, Korea: The emerging role of CGM in gestational diabetes: evidence and future directions

CGM and AID Digital innovation in diabetes Chair(s): Jun Sung Moon, Jee Hee Yoo Thursday 15 October, 16:50~17:50 Room 2

Continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems have fundamentally transformed the landscape of diabetes care, offering unprecedented opportunities for precision glycemic management. This session explores three core dimensions of diabetes technology: early initiation, pattern interpretation, and real-world adoption. By integrating evidence on optimal timing of CGM and AID use, practical approaches to translating glucose data into clinical decisions, and both patient and physician perspectives on technology in practice, this session aims to bridge the gap between digital innovation and everyday clinical application—equipping practitioners with actionable strategies for diverse patient populations.

RS9-L1 Viral N ShahIndiana University, USA: Early initiation of CGM and AID in T1D

RS9-L2 Seung-Hyun YooCatholic Kwandong University, Korea: The gap beyond the AGP: translating glucose patterns into prescribing decisions in type 2 diabetes and prediabetes

RS9-L3 Noriko KodaniNational Center for Global Health and Medicine, Japan: Diabetes technology from a patient's and physician's perspective

Panel discussion

RS9-P1
Yeoree YangThe Catholic University of Korea, Korea
RS9-P2
Sun-Joon MoonSungkyunkwan University, Korea
RS9-P3
Jun Hwa HongEulji University, Korea

Next-generation therapeutics Next-generation technologies and drugs targeting diabetic kidney and liver disease progression Chair(s): You-Cheol Hwang, Ho Chan Cho Thursday 15 October, 16:50~17:50 Room 3

Diabetic kidney and liver disease remain among the most pressing complications of diabetes, and next-generation therapeutics are entering a pivotal new phase. This session presents three advances: the clinical evaluation of CU01-1001 in diabetic kidney disease, Vanoglipel as the most advanced GPR119 agonist for MASH, and hepatic enzyme targeting as a strategy to suppress MASH progression, collectively bridging molecular targets with clinical application in diabetic organ complications.

RS10-L1 Kyuchang WonYeungnam University, Korea: The efficacy and safety of CU01-1001 in subjects with diabetic kidney disease (DKD)

RS10-L2 Mi-Kyung KimDong-A ST, Korea: Vanoglipel, the most advanced GPR119 agonist for MASH

RS10-L3 Jaewhan SongYonsei University, Korea: Targeting hepatic enzymes as a strategy to suppress MASH

Panel discussion

RS10-P1
Seung Soon ImKeimyung University, Korea
RS10-P2
Ju Youn KimHanyang University ERICA, Korea
RS10-P3
Eun Yeong HaKeimyung University, Korea

NT-proBNP in type 2 diabetes Clinical utility of NT-proBNP in the management of type 2 diabetes: from risk stratification to therapeutic decision-making Chair(s): Jioh Mok, In-Kyung Jeong Thursday 15 October, 16:50~17:50 Room 4

Once regarded primarily as a biomarker of heart failure, NT-proBNP is now emerging as a valuable tool for cardiovascular and cardiometabolic risk stratification in patients with type 2 diabetes. In this session, the Research Group on Diabetic Vascular Disease brings together global, cardiology, and endocrinology perspectives to critically evaluate the clinical utility of NT-proBNP in patients with type 2 diabetes. Specifically, the presentations will explore NT-proBNP as a global marker of cardiometabolic risk, its integration into diabetes care from a cardiology and endocrinology perspective, and its role in the early detection and management of heart failure among patients with type 2 diabetes.

RS11-L1 Ronald MaThe Chinese University of Hong Kong, China: NT-proBNP for cardiovascular disease risk assessment in people with diabetes: global evidence and emerging perspectives

RS11-L2 Ja Young JeonAjou University, Korea: Integrating NT-proBNP into diabetes care: implications for cardio-renal protection strategies

RS11-L3 Dong Hyuk ChoKorea University, Korea: NT-proBNP in the early detection and management of heart failure in patients with type 2 diabetes

Omics for clinical translation in diabetes Omics, diabetes, clinical translation Chair(s): Kyong Soo Park, Sung-Hoon Kim Thursday 15 October, 16:50~17:50 Room 5

Clinical translation of genomic discoveries is transforming diabetes care through polygenic risk prediction, population biobanks, and precision medicine. This session explores recent advances in type 1 diabetes genetics, polygenic risk scores, and large-scale East Asian biobank studies that bridge research and clinical practice. These efforts will facilitate earlier risk stratification and more personalized approaches to diabetes prevention and management.

RS12-L1 Stephen S. RichUniversity of Virginia, USA: Genetic basis of type 1 diabetes and utility of genetic risk scores across diverse genetic ancestries

RS12-L2 Daeeun KimSeoul National University, Korea: Polygenic risk scores and heterogeneity in metabolic diseases

RS12-L3 Wayne Huey-Herng SheuNational Health Research Institutes, Taiwan: Biobank studies for diabetes in East Asia – Taiwan experience

Diabetes, from data to new medicine (K) From infrastructure to impact Chair(s): WonHo Kim, Heung Yong Jin Thursday 15 October, 16:50~17:50 Room 6

Diabetes care is at an inflection point, moving from data to a new kind of medicine. This session bridges those two frontiers. We first trace how a nationwide, multi-center Common Data Model (CDM) cohort is evolving into an AI infrastructure for predicting diabetic complications, and then
explore how AI-driven prognostic management and prescription digital therapeutics are reshaping everyday clinical care. In a panel bringing together the Korea National Institute of Health, industry, and data-platform experts, we discuss how national data infrastructure can be translated into a new medicine that truly reaches patients.

RS13-L1 Sang Youl RheeKyung Hee University, Korea: From cohort to national infrastructure: multi-center CDM-based AI for predicting diabetic complications

RS13-L2 Yul HwangboNational Cancer Center, Korea: Diabetes care using digital twins and generative AI agents

Panel discussion

RS13-P1
Seung Hee LeeKorea National Institute of Health, Korea
RS13-P2
Hyosoung ChaWeknew Inc., Korea
RS13-P3
Yoori ImEvidNet, Korea
RS13-P4
Taehyun ParkODN Co.,Ltd., Korea

구분		사전등록 Early bird (~2026년 8월 10일까지)		사전등록 Advance (~2026년 9월 11일까지)		현장등록 (2026년 10월 15일 ~ 17일)
구분		KDA회원	비회원	KDA회원	비회원	KDA회원	비회원
Full Day 등록 (10월 15일~17일)	전문의 (개원의, 교수, 봉직의, 전임의 포함)	KRW 240,000	KRW 300,000	KRW 280,000	KRW 350,000	KRW 370,000	KRW 450,000
Full Day 등록 (10월 15일~17일)	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사, 관련분야 교수 및 기타 (군의관 및 공중보건의 포함)	KRW 140,000	KRW 200,000	KRW 180,000	KRW 230,000	KRW 250,000	KRW 270,000
One-day 등록	전문의 (개원의, 교수, 봉직의, 전임의 포함)	KRW 150,000	KRW 180,000	KRW 170,000	KRW 210,000	KRW 220,000	KRW 270,000
One-day 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사, 관련분야 교수 및 기타 (군의관 및 공중보건의 포함)	KRW 100,000	KRW 120,000	KRW 120,000	KRW 140,000	KRW 140,000	KRW 160,000
저녁 식사	전체	KRW 55,000
For Korean 전공의 / 의과대학생 / 대학원생(기초, 간호, 영양, 기타 관련 분야) 할인 적용		KRW 50,000 당뇨병학에 관심있는 젊은 연구자 및 전공의를 위한 할인 등록을 제공하고 있습니다. 대한당뇨병학회 회원 추천서 필수 제출 ←클릭 시, 다운로드 할인 등록은 Full-registration으로만 등록이 가능합니다.

Program details

평점안내 (For Korean)